BACKGROUND: Hepatitis B vaccine provides a model for improving uptake and completion of multidose vaccinations in the drug-using community. METHODS: The Drugs, AIDS, STDs, and Hepatitis (DASH) project conducted a randomized controlled trial among not-in-treatment current drug users in 2 urban neighborhoods. Neighborhoods were cluster-randomized to receive a standard behavioral intervention (which provided information on human immunodeficiency virus [HIV]) or an enhanced behavioral intervention (designed to increase acceptance of or adherence to the hepatitis B vaccination protocol). Participants within clusters were randomized to a standard vaccination schedule (vaccines at 0, 1, and 6 months) or an accelerated vaccination schedule (vaccines at 0, 1, and 2 months). The outcomes were completion of the 3-dose vaccine and seroprotection against hepatitis B virus (HBV). RESULTS: Of participants with negative screening results for HIV and HBV, 77% accepted hepatitis B vaccination, and 75% of vaccinees received all 3 doses. Injection drug users (IDUs) on the accelerated schedule were significantly more likely to receive 3 doses (76%) than those on the standard schedule (66%; P = .04), although for drug users as a whole the corresponding adherence rates were 77% and 73%, respectively. No difference in adherence was observed between the behavioral intervention groups. Predictors of adherence were older age, African American race, stable housing, and alcohol use. Cumulative HBV seroprotection (≥10 mIU/mL) was gained within 12 months by 65% of those completing the schedule. Seroprotection at 6 months was greater for those on the accelerated schedule. CONCLUSION: The accelerated vaccination schedule improves hepatitis B vaccination adherence among IDUs.
RCT Entities:
BACKGROUND:Hepatitis B vaccine provides a model for improving uptake and completion of multidose vaccinations in the drug-using community. METHODS: The Drugs, AIDS, STDs, and Hepatitis (DASH) project conducted a randomized controlled trial among not-in-treatment current drug users in 2 urban neighborhoods. Neighborhoods were cluster-randomized to receive a standard behavioral intervention (which provided information on human immunodeficiency virus [HIV]) or an enhanced behavioral intervention (designed to increase acceptance of or adherence to the hepatitis B vaccination protocol). Participants within clusters were randomized to a standard vaccination schedule (vaccines at 0, 1, and 6 months) or an accelerated vaccination schedule (vaccines at 0, 1, and 2 months). The outcomes were completion of the 3-dose vaccine and seroprotection against hepatitis B virus (HBV). RESULTS: Of participants with negative screening results for HIV and HBV, 77% accepted hepatitis B vaccination, and 75% of vaccinees received all 3 doses. Injection drug users (IDUs) on the accelerated schedule were significantly more likely to receive 3 doses (76%) than those on the standard schedule (66%; P = .04), although for drug users as a whole the corresponding adherence rates were 77% and 73%, respectively. No difference in adherence was observed between the behavioral intervention groups. Predictors of adherence were older age, African American race, stable housing, and alcohol use. Cumulative HBV seroprotection (≥10 mIU/mL) was gained within 12 months by 65% of those completing the schedule. Seroprotection at 6 months was greater for those on the accelerated schedule. CONCLUSION: The accelerated vaccination schedule improves hepatitis B vaccination adherence among IDUs.
Authors: D C Des Jarlais; D G Fisher; J C Newman; B N Trubatch; M Yancovitz; D Paone; D Perlman Journal: Am J Public Health Date: 2001-11 Impact factor: 9.308
Authors: Robin van Houdt; Gerard J B Sonder; Nicole H T M Dukers; Lian P M J Bovee; Anneke van den Hoek; Roel A Coutinho; Sylvia M Bruisten Journal: Vaccine Date: 2006-07-12 Impact factor: 3.641
Authors: Sharon J Hutchinson; Sarah Wadd; Avril Taylor; Sheila M Bird; Alan Mitchell; David S Morrison; Syed Ahmed; David J Goldberg Journal: Vaccine Date: 2004-11-25 Impact factor: 3.641
Authors: Joseph Cox; Prithwish De; Carole Morissette; Claude Tremblay; Randolph Stephenson; Robert Allard; Lisa Graves; Elise Roy Journal: Soc Sci Med Date: 2007-10-24 Impact factor: 4.634
Authors: Jacquelyn Slomka; Sheryl McCurdy; Eric A Ratliff; Sandra Timpson; Mark L Williams Journal: J Gen Intern Med Date: 2007-08-01 Impact factor: 5.128
Authors: Evan S Herrmann; Alexis K Matusiewicz; Maxine L Stitzer; Stephen T Higgins; Stacey C Sigmon; Sarah H Heil Journal: J Subst Abuse Treat Date: 2016-06-24
Authors: Jason Grebely; Geert Robaeys; Philip Bruggmann; Alessio Aghemo; Markus Backmund; Julie Bruneau; Jude Byrne; Olav Dalgard; Jordan J Feld; Margaret Hellard; Matthew Hickman; Achim Kautz; Alain Litwin; Andrew R Lloyd; Stefan Mauss; Maria Prins; Tracy Swan; Martin Schaefer; Lynn E Taylor; Gregory J Dore Journal: Int J Drug Policy Date: 2015-07-17
Authors: Carolyn Z Grimes; Lu-Yu Hwang; Peng Wei; Dimpy P Shah; Kelly A Volcik; Eric L Brown Journal: J Gen Virol Date: 2012-11-14 Impact factor: 3.891
Authors: Verughese Jacob; Sajal K Chattopadhyay; David P Hopkins; Jennifer Murphy Morgan; Adesola A Pitan; John M Clymer Journal: Am J Prev Med Date: 2016-02-01 Impact factor: 5.043
Authors: Carmen L Masson; Kevin L Delucchi; Courtney McKnight; Jennifer Hettema; Mandana Khalili; Albert Min; Ashly E Jordan; Nicole Pepper; Jessica Hall; Nicholas S Hengl; Christopher Young; Michael S Shopshire; Jennifer K Manuel; Lara Coffin; Hali Hammer; Bradley Shapiro; Randy M Seewald; Henry C Bodenheimer; James L Sorensen; Don C Des Jarlais; David C Perlman Journal: Am J Public Health Date: 2013-08-15 Impact factor: 9.308